Nasal spray shows promise for depression that Won't quit
NCT ID NCT05660642
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new nasal spray called BPL-003, combined with psychological support, in 64 people with treatment-resistant depression (depression that hasn't improved with at least two prior medications). The goal is to see if it's safe and how it affects mood. Participants will receive one or two doses and be monitored for side effects and changes in depression symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BPL-003 (intranasal)
What this could lead to
If successful, this could point toward a new treatment option for people with depression that hasn't responded to standard medications.
What could go wrong
This is an early Phase 2a study with only 64 participants, open-label (no placebo), so results may not be definitive. Risks include side effects and potential for suicidal thoughts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT RESISTANT DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hammersmith Medicines Research
RECRUITINGLondon, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
King's College London, Clinical Trials Facility
COMPLETEDLondon, United Kingdom
-
MAC Clinical Research
RECRUITINGLiverpool, L34 1BH, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••